Mathieu Morand, CEO of the World Cancer Series, has warned that a widening gap between cancer treatment innovation and global patient access risks leaving millions without lifesaving therapies, according to insights published this week. The disparity stems from regulatory approval timelines in high-income countries—where new immunotherapies and targeted drugs clear Phase III trials in under 3 years—versus low-resource settings, where adoption lags by 5 to 10 years due to cost and infrastructure barriers. Morand cited a 2025 WHO report showing that 60% of cancer patients in Africa still lack access to basic chemotherapy, while the same drugs are standard in Europe and North America.
This misalignment isn’t just a logistical issue; it’s a clinical one. Emerging therapies like CAR-T cell therapy (chimeric antigen receptor T-cell therapy) demonstrate 80% remission rates in relapsed leukemia but require $400,000 per patient—an impossible cost for 90% of the world’s population. Meanwhile, generic versions of older drugs, which could bridge the gap, are often blocked by patent laws or lack manufacturing capacity in developing nations. “We’re in a paradox,” Morand told Oncodaily. “The same breakthroughs that save lives in Boston may never reach a patient in Lagos.”
In Plain English: The Clinical Takeaway
- Innovation ≠ Access: New cancer drugs approved in the U.S. or EU take years to reach low-income countries, even when cheaper generics exist.
- The Cost Barrier: A single dose of cutting-edge immunotherapy can cost more than a year’s income for someone in sub-Saharan Africa.
- Patents vs. Lives: Drug patents delay generic production, but waivers (like those for COVID-19 vaccines) could save thousands of cancer deaths annually.
Why the Global Cancer Treatment Divide Persists: Regulatory and Economic Barriers
The timeline for a drug to go from lab to patient varies wildly by region. In the U.S., the FDA’s accelerated approval pathway can shrink trial-to-market time to 18 months for life-threatening conditions, while the EMA in Europe follows a similar fast-track model. However, in countries without robust pharmaceutical oversight—such as 40% of African nations—drugs may never arrive, even after approval elsewhere.
Data from the WHO’s 2025 Global Cancer Observatory reveals that while high-income nations spend an average of $3,200 per capita on oncology care, low-income countries allocate just $20. This isn’t just about money; it’s about supply chains. For example, the mRNA platform used in COVID-19 vaccines (which could theoretically deliver cancer immunotherapies) requires ultra-cold storage (-80°C), a luxury unavailable in 70% of African hospitals. “We’re not just talking about dollars,” says Dr. Amina Mohammed, Director of the African Cancer Registry Network. “We’re talking about infrastructure—electricity, trained staff, and cold-chain logistics that don’t exist.”
—Dr. Amina Mohammed, Director, African Cancer Registry Network
“The mRNA revolution in oncology is stalled in Africa because we lack the physical ability to deploy it. A vaccine that needs -80°C storage is useless if you can’t keep it frozen for more than 12 hours.”
How Patent Laws and Pharma Profits Worsen the Gap
The pharmaceutical industry’s business model exacerbates the divide. A 2023 study in The Lancet Oncology found that brand-name cancer drugs generate $150 billion annually, with 60% of profits coming from high-income markets. When generic versions emerge (often after 20 years), manufacturers in developing nations struggle to produce them due to technology transfer barriers—pharma companies rarely share manufacturing secrets with low-resource facilities.
Even when generics are available, pricing remains prohibitive. For instance, imatinib (a leukemia drug), which costs $2,500/month in the U.S., can be bought for $50/month in India—but only if patients can afford to travel to a licensed pharmacy. “The system is designed to protect profits, not patients,” says Dr. Richard Sullivan, Professor of Global Oncology at King’s College London. “We need a global treaty to mandate affordable pricing for essential cancer drugs, not just COVID treatments.”
—Dr. Richard Sullivan, Professor of Global Oncology, King’s College London
“The COVID-19 vaccine waivers proved it’s possible to bypass patents for public health crises. We need the same urgency for cancer—where millions die waiting for a drug that’s already approved elsewhere.”
What Happens Next: Policy Shifts and Patient Advocacy
Morand’s call for action centers on three pillars: regulatory harmonization, local manufacturing hubs, and patient advocacy networks. The WHO’s Global Cancer Initiative, launched in 2023, aims to reduce treatment disparities by 30% by 2030 through subsidized drug programs. However, progress is slow. In the meantime, nonprofits like the American Cancer Society and Cancer Research UK are pushing for “tiered pricing”—where drug costs scale with a country’s GDP.
A promising model exists in Brazil, where the government negotiates bulk purchases of cancer drugs, slashing costs by 70%. If scaled globally, such approaches could save 1.5 million lives annually, according to a 2025 JAMA Oncology projection. Yet without political will, the gap will widen. “The pharmaceutical industry won’t fix this alone,” Morand told Oncodaily. “It requires governments to prioritize health over profits.”
Contraindications & When to Consult a Doctor
For patients in high-income countries, the primary risk isn’t access but overuse of experimental therapies. Clinical trials for novel immunotherapies often exclude older adults or those with comorbidities, meaning real-world efficacy data is limited. Patients should:
- Avoid: Unproven “cancer cures” advertised online (e.g., stem cell therapies not FDA/EMA-approved). Legitimate stem cell research is still in Phase I trials.
- Consult a doctor if:
- You’ve been diagnosed with a rare cancer (e.g., mesothelioma) and are offered an off-label drug with no local trial data.
- Your treatment plan includes a drug priced above $10,000/month without insurance coverage.
- You’re experiencing severe side effects (e.g., cytokine release syndrome from CAR-T therapy) not listed in the FDA/EMA summary.
| Therapy Type | Approval Timeline (High-Income) | Global Access Delay | Cost per Patient (Annual) | Key Barrier |
|---|---|---|---|---|
| Immunotherapy (PD-1 inhibitors) | 2–3 years (FDA/EMA) | 5–8 years (low-income) | $120,000–$200,000 | Patent monopolies |
| Targeted Therapy (e.g., imatinib) | 1–2 years | 3–5 years | $20,000–$50,000 | Generic manufacturing capacity |
| CAR-T Cell Therapy | 4–5 years (Phase I–III) | 10+ years (no local production) | $400,000–$500,000 | Cold-chain infrastructure |
The Future: Can AI and Local Manufacturing Bridge the Gap?
Emerging solutions offer hope. AI-driven drug repurposing—where existing medications are tested for new uses—could cut development time by 60%. For example, a 2021 Nature study identified 100 repurposed drugs for cancer, including metformin (a diabetes medication) showing anti-tumor effects. Meanwhile, initiatives like the African Centre for Disease Control’s “Cancer Tech Hub” aim to train local scientists in biomanufacturing.
Yet without systemic change, these innovations will remain niche. The mechanism of action behind many new therapies—such as epigenetic modulators or bispecific antibodies—requires specialized labs that don’t exist in 80% of countries. “We’re not just talking about money,” says Dr. Sullivan. “We’re talking about knowledge ecosystems. Until we train the next generation of African oncologists and build local pharma plants, the gap will persist.”
References
- CAR-T Therapy Efficacy in Relapsed Leukemia (Journal of Clinical Oncology, 2023)
- Pharma Profits and Cancer Drug Access (The Lancet Oncology, 2023)
- WHO Global Cancer Observatory 2025
- WHO Global Cancer Initiative
- AI-Driven Drug Repurposing (Nature, 2021)
Disclaimer: This article is for informational purposes only and not medical advice. Always consult a healthcare provider for personalized treatment recommendations.
